Evidence map›Paper›PMID 40167945›Full record

ArticleEJNMMI research2025

3'-deoxy-3'-

Masayuki Sato, Yukihiro Umeda, Tetsuya Tsujikawa, Tetsuya Mori, Akikazu Shimada, Tomoaki Sonoda, Makiko Yamaguchi, Chisato Honjo, Yuko Waseda, Yasushi Kiyono and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Masayuki SatoDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.
Yukihiro UmedaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan. umeda@u-fukui.ac.jp.ORCID http://orcid.org/0000-0002-9826-6856
Tetsuya TsujikawaDepartment of Radiology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.
Tetsuya MoriBiomedical Imaging Research Center, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.
Akikazu ShimadaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.
Tomoaki SonodaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.
Makiko YamaguchiDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.
Chisato HonjoDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.
Yuko WasedaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.
Yasushi KiyonoBiomedical Imaging Research Center, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.
Tamotsu IshizukaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.
Hidehiko OkazawaBiomedical Imaging Research Center, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, 910-1193, Fukui, Japan.

Funding

MEXT KAKENHI JP22K07688
6 · The paper itself

Abstract

backgroundAnti-programmed cell death-1 (anti-PD-1) therapy has become the standard immunotherapy for patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the organs influenced by PD-1 inhibitors on a patient's tumor immunity. We examined the changes in lymphoid tissue proliferation before and after PD-1 inhibitor treatment using 3'-deoxy-3'-[

resultsThe baseline

conclusionsIn patients with advanced NSCLC who achieved a tumor response, proliferation decreased in the bone marrow, but not in the spleen or lymph nodes, 6 weeks after treatment initiation.

Indexed as

18F-FLT PETBone marrowLung cancerPD-1 inhibitorProliferationSpleen

Identifiers

PMID40167945
PMCPMC11961847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.